Physician profile
Mark A Willoughby
NPI 1215931993
$41,435.22
in general payments reported to CMS, 2019-2025
30 companies · $1,307 in 2025
The $1,307 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $904 · 2020: $303 · 2021: $710 · 2022: $36K · 2023: $763 · 2024: $1,226 · 2025: $1,307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,776 · Education: $520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,776.13 |
| Education | $520.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Icad, INC | $35,500.00 | 2022 | |
| Janssen Biotech, INC. | $1,214.71 | 2019-2025 | Tremfya, Remicade, Simponi |
| Abbvie INC. | $1,070.99 | 2019-2025 | Rinvoq, Skyrizi |
| Incyte Corporation | $402.74 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $394.93 | 2019-2025 | Dupixent, Libtayo |
| Pfizer INC. | $337.15 | 2019-2025 | |
| Amgen INC. | $285.43 | 2019-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $254.27 | 2019-2023 | |
| Strata Skin Sciences, INC. | $229.70 | 2022-2025 | Xtrac |
| Biofrontera INC. | $212.12 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Allergan, INC. | $196.01 | 2019-2022 | |
| Lilly USA, LLC | $182.04 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $176.60 | 2019-2025 | |
| Ucb, INC. | $157.25 | 2021-2024 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $140.43 | 2023-2025 | Zoryve |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dusa Pharmaceuticals, INC. | $114.94 | 2019 | |
| Vyne Pharmaceuticals INC. | $100.31 | 2020-2021 | |
| Almirall LLC | $90.47 | 2019-2024 | Klisyri |
| E.R. Squibb & Sons, L.L.C. | $65.26 | 2024 | Sotyktu |
| Celgene Corporation | $57.43 | 2019 | |
| Genzyme Corporation | $46.87 | 2021-2023 | |
| Galderma Laboratories, L.P. | $31.75 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $29.51 | 2019-2021 | |
| Merz North America, INC. | $27.99 | 2024 | |
| Sanofi-Aventis U.S. LLC | $23.99 | 2020 | |
| Leo Pharma INC. | $23.05 | 2023 | Adbry |
| Botanix Sb INC | $19.99 | 2025 | Sofdra |
| Helsinn Therapeutics (U.S.), INC. | $16.97 | 2025 | Valchlor |
| Dermira, INC. | $16.21 | 2019 | |
| Cipher Pharmaceuticals US LLC | $16.11 | 2025 | Natroba, Spinosad |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Willoughby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.